Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.

Expert Comments:

Katherine Genis, Edison Investment Research (8/19/15)
"Mesoblast Ltd.'s pipeline continues to mature steadily. The filing of MSC-100-IV by partner JCR in graft-versus-host disease (GVHD) in Japan in late 2014 marked Mesoblast's first product submission. A regulatory decision is likely in mid-2015. . .Mesoblast is the leading mesenchymal stem cell (MSC) development company, with two platforms (mesenchymal precursor cells and MSCs) and nine clinical candidates in Phase 2 and 3. Alliances with Teva, CR, Celgene and Lonza underpin the key late-stage programs."

Kevin DeGeeter, Ladenburg Thalmann (8/17/15)
"Mesoblast Ltd. remains on track to present six-month topline data by the end of October from a 48-patient Phase 2 study to treat rheumatoid arthritis (RA) patients refractory to TNF-alpha inhibitors. . .strong data could provide a meaningful catalyst for Mesoblast shares and have a positive impact on the company's publicly disclosed process to license rights of certain systemically delivered mesenchymal precursor cell programs. As such, we view the upcoming data readout as a low-risk/high-reward catalyst for investors and would look to accumulate Mesoblast shares prior to the announcement."

Jason Kolbert, Maxim Group (8/17/15)
"We view Mesoblast Ltd.'s revisions to the Phase 3 pivotal trial in heart failure as very positive as the interim analysis at 50% HF-MACE events will test for superiority. If that happens, we could see a fast track pathway to the global marketplace emerge."

Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research) (7/24/15)
"Mesoblast Ltd. announced that results of the Phase 2 trial of its intravenously delivered mesenchymal precursor cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. . .the Phase 2 randomized, single-blind, placebo-controlled trial was conducted across 18 sites in the U.S. and evaluated the effects of a single intravenous infusion of 0.3, 1 or 2 million MPCs/kilogram or placebo over 12 weeks in 61 patients with a mean diabetes duration of 10 years."

Henry McCusker, Regenerative Medicine Investors (7/23/15)
"Mesoblast Ltd. today announced that results of the Phase 2 trial of its intravenously delivered mesenchymal precursor cells (MPCs) for the treatment of type 2 diabetes. . .the primary endpoint of safety was safe and well tolerated, with no treatment-related adverse events and no serious adverse events over the 12-week study period. There were no anti-human leukocyte antigen antibody immune responses against MPC donor antigens identified in any subject."

Katherine Genis, Edison Investment Research (7/23/15)
"Mesoblast Ltd.'s recent agreement with Celgene Corp., which entailed a net AU$58.5M equity purchase in return for first right of refusal on products in certain disease areas, provides Mesoblast with a capital injection and potential development/commercialization partner. Meanwhile, an imminent regulatory decision in Japan for MSC-100-IV in acute graft versus host disease could prove a significant share price catalyst; if approved, MSC-100-IV would be the company's first product to market."

More Expert Comments

Experts Commenting on This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Henry McCusker – Regenerative Medicine Investors
Henry McCusker, Founder and Director of Research – Scimitar Equity
Alain Vertes, Managing Director – NxR Biotechnologies GmbH
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Mesoblast Ltd. Content